Shareholders approve merger making Bio‑Techne (TECH) a Merck KGaA subsidiary. FY2025 sales $1.22B; segment breakdown, risks and strategy for investors.
Bio-Techne (TECH) signs merger agreement with Merck KGaA. Analysis of strategic fit, segment exposure, and regulatory risks for investors.